• Vicore Pharma Holding posted Q2 operating loss of SEK 150.1 million, widening 34.98% from a year earlier.
• Net revenues rose 29.41% to SEK 2.2 million; net loss widened 23.74% to SEK 142.8 million.
• Cash, cash equivalents, short-term investments fell to SEK 905.6 million as of June 30 from SEK 1.17 billion at Dec. 31.
• Completed ASPIRE Phase 2b enrollment in IPF, topping 360 patients across more than 100 sites; topline results expected mid-2027.
• Commenced Nasdaq US trading in July under “VCRE”; CEO Ahmed Mousa said the quarter marked a shift toward executing for the readout.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vicore Pharma Holding AB published the original content used to generate this news brief on August 21, 2026, and is solely responsible for the information contained therein.